CLAIMS

1.   An examination method to predict prognostic effects in immunotherapy for pancreas cancer, comprising determination of intrinsic IL-12-producing ability.

2.   The examination method according to claim 1, wherein the prognostic effects are predicted by dividing the IL-12-producing ability into a plurality of, i.e. at least three groups of 50 pg/ml or more, from 7.8 to less than 50 pg/ml, and less than 7.8 pg/ml.

3.   The examination method according to claim 1 or 2, wherein the immunotherapy is an IL-12 production-inducing agent.

4.   The examination method according to any one of claims 1 to 3, wherein the IL-12 production-inducing agent is a substance having a β-1,3/1,6 glucan structure.

5.   An IL-12 production-inducing agent, wherein the IL-12 production-inducing agent is administered to a pancreatic cancer patient having IL-12-producing ability of less than 7.8 pg/ml in the examination

according to any one of claims 1 to 4.

6.   A   cancer   therapeutic   agent   comprising
Gemcitabine Hydrochloride as principal component,
wherein the agent is used at least in combination with
an IL-12 production-inducing agent.

7.   The cancer therapeutic agent according to claim
6, wherein the cancer is pancreas cancer.

8.   The cancer therapeutic agent according to claim
6 or 7, wherein the IL-12 production-inducing agent
is administered to a pancreatic cancer patient having
IL-12-producing ability of less than 7.8 pg/ml.